Search Within

David Henry Aggen

Formats
  1. Meeting Abstract (45)
  2. Journal Article (10)
  3. Editorial (2)
  4. Research Letter (2)
  5. Review (1)
Groups
  1. Department of Medicine (60)
  2. Genitourinary Oncology Service (60)
  3. Hematologic Malignancies, Division of (60)
  4. Solid Tumor Oncology Division (60)
  5. Weinberg Fellows (42)
  6. Graduate Medical Education (38)

More Groups

People
  1. Jonathan Rosenberg (31)
  2. Gopakumar Iyer (29)
  3. Dean Bajorin (26)
  4. Samuel Funt (26)
  5. Min Yuen Teo (25)
  6. Chung-Han Lee (22)

More People

Years
  1. 2025 (9)
  2. 2024 (17)
  3. 2023 (12)
  4. 2022 (10)
  5. 2021 (7)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (4)
  3. Cancer Research (3)
  4. European Urology (3)
  5. Journal for ImmunoTherapy of Cancer (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (38)
  2. American Association for Cancer Research (7)
  3. Biomed Central Ltd (3)
  4. Elsevier Science, Inc. (3)
  5. Elsevier Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer
    Journal Article

    Dallos, M. C.; Obradovic, A. Z.; McCann, P.; Chowdhury, N.; Pratapa, A.; Aggen, D. H.; Gaffney, C.; Autio, K. A.; Virk, R. K.; De Marzo, A. M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma
    Meeting Abstract

    Aggen, D. H.; Garcia, A.; Saro Suarez, J. M.; Sauer, A.; Cristiani, S.; Brophy, F. E.; Streets, S.; Norry, E.; Nelson, A. A.; Kilari, D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma
    Meeting Abstract

    Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors
    Meeting Abstract

    Aggen, D. H.; McKean, M.; Hoffman-Censits, J. H.; Lakhani, N. J.; Alhalabi, O.; Guancial, E. A.; Bashir, B.; Bowman, I. A.; Tan, A.; Lingaraj, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Badri, A.; Guercio, B. J.; Ratna, N.; Gavrilov, D.; Metzker, N.; Duzgol, C.; Teo, M. Y.; Regazzi, A. M.; Supplice, L.; Funt, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Jacobi, R.; Aggen, D. H.; McHugh, D. J.; Shah, N. J.; Carlo, M. I.; Keegan, N. M.; Gayadin, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save